Drug-Induced Polyneuropathy Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 17 studies associated with Drug-Induced Polyneuropathy.
Here is a small sampling of Drug-Induced Polyneuropathy studies by title:
- Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents
- A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse
- Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy
- Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy
- Changes in the expression of endocannabinoid system components in an experimental model of chemotherapy-induced peripheral neuropathic pain: Evaluation of sex-related differences
Components of the Drug-Induced Polyneuropathy Research Dashboard
- Dosing information available for Drug-Induced Polyneuropathy
- Chemotype guidance for treating Drug-Induced Polyneuropathy with cannabis
- Synopsis of cannabis research for Drug-Induced Polyneuropathy
- Individual study details for Drug-Induced Polyneuropathy
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Cannabinoids & Endocannabinoids
- Study Result
- Year of Publication
Overview - Drug-Induced Polyneuropathy
Description of Drug-Induced Polyneuropathy
Drug-induced peripheral neuropathies induced by chemotherpy agents for example are a major side effects of cancer treatment that can last long after the treatment regimen is completed. To date orthodox medicine has no FDA approved treatment for CIPN.
Diseases of the Nervous System
ICD-10 Code: G62.0
Drug-Induced Polyneuropathy Symptoms:
Peripheral nerve pain (e.g. numbness, tingling, sharp, hot, or freezing pain), weakness to affected body part
Also known as:
CIPN, Chemotherapy induced peripheral neuropathy
THC Interaction with Pharmaceutical Drugs
- THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example.
- THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin). Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
- Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
CBD Interaction with Pharmaceutical Drugs
- CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
- Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.